Despite the worldwide impact of dementia and decades of studies, there is currently no cure for this disabling condition. Accumulating evidence has proven the role of metabolic diseases (such as type-2 diabetes and obesity) on the development of dementia in Alzheimer’s disease and in vascular dementia, particularly in the aged population. However, the underlying mechanisms are yet to be elucidated.
Aging is associated with an increase in oxidative stress, amyloid-β accumulation, and neuroinflammation, in the brain. These cytotoxic processes result in cerebrovascular and neuronal changes potentially leading to cognitive impairment. In recent studies, metabolic diseases were shown to exacerbate cerebrovascular pathologies by aggravating age-related cytotoxic factors and were implicated in the pathogenesis of neurocognitive disorders. These findings highlight the pathological significance of metabolic diseases and cerebrovascular changes in the development of dementia.
This research topic aims to provide novel insights into neurocognitive disorders, in terms of metabolic and/or neurological aspects. This would allow a comprehensive understanding of the complex pathogenesis of these disorders. Furthermore, we hope that crosstalk between metabolic and neurologic approaches would lead to innovative solutions with the development of novel preventive and/or treatment strategies for neurocognitive impairment. For instance, some medications for metabolic diseases might have beneficial effects on Alzheimer’s disease and vascular cognitive impairment. In this respect, this topic will include cross-cutting studies, as well as specialized studies, on metabolic and cerebrovascular diseases..
For this purpose, we welcome all types of articles accepted by the journal policies: Original articles, Review, Mini-Review, Opinions, Perspectives, Methods etc. The areas related to this research topic may include, but are not limited to, the following themes:
- Implications of type 2 diabetes on cognitive impairment and the underlying mechanisms;
- Effects of obesity on cognitive impairment and the underlying mechanisms;
- Pathogenesis of neurocognitive disorders, including cerebrovascular diseases and vascular dementia;
- Novel mechanistic insights on Alzheimer’s disease and other age-related dementias; and
- Innovative interventional strategies using pharmacological (i.e., drug repositioning and new bioactive molecules) or non-pharmacological approaches for dementia and age-related neurological disorders.
This research topic is cross-listed in Frontiers in Endocrinology and Frontiers in Aging Neuroscience. Authors can select which of these journals they would like to submit to when they click the "Submit" button at the top of this page.
Despite the worldwide impact of dementia and decades of studies, there is currently no cure for this disabling condition. Accumulating evidence has proven the role of metabolic diseases (such as type-2 diabetes and obesity) on the development of dementia in Alzheimer’s disease and in vascular dementia, particularly in the aged population. However, the underlying mechanisms are yet to be elucidated.
Aging is associated with an increase in oxidative stress, amyloid-β accumulation, and neuroinflammation, in the brain. These cytotoxic processes result in cerebrovascular and neuronal changes potentially leading to cognitive impairment. In recent studies, metabolic diseases were shown to exacerbate cerebrovascular pathologies by aggravating age-related cytotoxic factors and were implicated in the pathogenesis of neurocognitive disorders. These findings highlight the pathological significance of metabolic diseases and cerebrovascular changes in the development of dementia.
This research topic aims to provide novel insights into neurocognitive disorders, in terms of metabolic and/or neurological aspects. This would allow a comprehensive understanding of the complex pathogenesis of these disorders. Furthermore, we hope that crosstalk between metabolic and neurologic approaches would lead to innovative solutions with the development of novel preventive and/or treatment strategies for neurocognitive impairment. For instance, some medications for metabolic diseases might have beneficial effects on Alzheimer’s disease and vascular cognitive impairment. In this respect, this topic will include cross-cutting studies, as well as specialized studies, on metabolic and cerebrovascular diseases..
For this purpose, we welcome all types of articles accepted by the journal policies: Original articles, Review, Mini-Review, Opinions, Perspectives, Methods etc. The areas related to this research topic may include, but are not limited to, the following themes:
- Implications of type 2 diabetes on cognitive impairment and the underlying mechanisms;
- Effects of obesity on cognitive impairment and the underlying mechanisms;
- Pathogenesis of neurocognitive disorders, including cerebrovascular diseases and vascular dementia;
- Novel mechanistic insights on Alzheimer’s disease and other age-related dementias; and
- Innovative interventional strategies using pharmacological (i.e., drug repositioning and new bioactive molecules) or non-pharmacological approaches for dementia and age-related neurological disorders.
This research topic is cross-listed in Frontiers in Endocrinology and Frontiers in Aging Neuroscience. Authors can select which of these journals they would like to submit to when they click the "Submit" button at the top of this page.